Clinical Trial Update: M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial update for M7824 in unresectable stage III non-small cell lung cancer has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• M7824 (bintrafusp alfa)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-01-16